STSSW has fundamentally transformed from an innovative medical device manufacturer to a distribution-focused enterprise while experiencing massive financial deterioration with net losses expanding by nearly 3,000%.
The company has abandoned its core identity as a manufacturer of patented smart-safety syringes and is now positioning itself as a medical device distributor, representing a complete strategic pivot. The dramatic increase in outstanding shares from 16.3M to 38.7M suggests significant dilutive equity raises, while the company appears to be liquidating manufacturing operations and pivoting to a lower-margin distribution model.
Despite stockholders' equity surging from $2.0M to $264.4M due to equity raises, operational performance collapsed catastrophically with net losses expanding from $9.3M to $282.5M. The company dramatically reduced R&D spending by 92% and cut inventory by 65.5%, while SG&A expenses tripled, indicating a shift away from manufacturing toward distribution operations. The massive equity infusion appears to be funding significant operational losses as the company transitions its business model, creating substantial dilution risk for existing shareholders.
Equity base grew 13144.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Asset base grew 3579% — expansion through organic growth, acquisitions, or capital deployment.
Net income declined 2938.9% — review whether driven by operations, interest costs, or non-recurring items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Cash position surged 1101.6% — strong cash generation or capital raise providing significant financial cushion.
Current assets grew 494.9% — improving short-term liquidity or inventory/receivables build.
SG&A up 218.7% — significant increase in sales or administrative costs, monitor impact on operating leverage.
R&D spending cut 92% — could signal cost discipline or concerning reduction in innovation investment.
Capex reduced 80.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Inventory drawn down 65.5% — strong sell-through or deliberate destocking; watch for supply constraints.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →